Diabetes drug may calm inflamed arteries in heart patients
NCT ID NCT05427084
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether canagliflozin, a diabetes medication, can reduce inflammation in the arteries of people with type 2 diabetes and stable coronary artery disease. Researchers will compare the drug to a placebo over 6 months in 16 participants. The main goal is to measure changes in artery inflammation using a special imaging scan.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Ottawa Heart Institute
RECRUITINGOttawa, Ontario, K1Y 4W7, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Software-Guided heart procedures: a new standard for coronary care?
- Heart patients may stay active longer with coach calls and group support
- Sitting less could be a lifeline for frail hearts – a new trial tests a simple program
- Can balloon timing make or break heart artery success?
- Can we predict which heart aneurysms will grow?
- Can a higher dose of adenosine sharpen heart scans?